Stock Track | LeMaitre Vascular Plunges 9% in Pre-Market on Q4 Revenue Miss and Weak Q1 Outlook

Stock Track

Feb 28, 2025

LeMaitre Vascular (LMAT) stock is experiencing a sharp pre-market plunge of 9% on Friday, following the company's fourth-quarter 2024 earnings report and disappointing first-quarter 2025 guidance released after the market close on Thursday.

The medical device maker reported Q4 2024 earnings per share (EPS) of $0.49, in line with analysts' estimates. However, the company's Q4 revenue of $55.7 million missed Wall Street's consensus estimate of $56 million. This revenue miss appears to be the primary driver behind the stock's steep decline in pre-market trading.

Adding to investor concerns, LeMaitre's Q1 2025 revenue guidance of $56.7-$58.7 million also fell short of analysts' expectations, further exacerbating the sell-off. While the company's Q1 EPS guidance range of $0.48-$0.53 was in line with estimates, the weak revenue outlook overshadowed this positive aspect, weighing heavily on the stock's performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1180401008"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180401008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180401008?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180401008","market":"us","top_or_hot":-1,"title":"Stock Track | LeMaitre Vascular Plunges 9% in Pre-Market on Q4 Revenue Miss and Weak Q1 Outlook","media":"Stock Track","content":"<p>LeMaitre Vascular (LMAT) stock is experiencing a sharp pre-market plunge of 9% on Friday, following the company's fourth-quarter 2024 earnings report and disappointing first-quarter 2025 guidance released after the market close on Thursday.</p>\n\n<p>The medical device maker reported Q4 2024 earnings per share (EPS) of $0.49, in line with analysts' estimates. However, the company's Q4 revenue of $55.7 million missed Wall Street's consensus estimate of $56 million. This revenue miss appears to be the primary driver behind the stock's steep decline in pre-market trading.</p>\n\n<p>Adding to investor concerns, LeMaitre's Q1 2025 revenue guidance of $56.7-$58.7 million also fell short of analysts' expectations, further exacerbating the sell-off. While the company's Q1 EPS guidance range of $0.48-$0.53 was in line with estimates, the weak revenue outlook overshadowed this positive aspect, weighing heavily on the stock's performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LeMaitre Vascular Plunges 9% in Pre-Market on Q4 Revenue Miss and Weak Q1 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LeMaitre Vascular Plunges 9% in Pre-Market on Q4 Revenue Miss and Weak Q1 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LeMaitre Vascular (LMAT) stock is experiencing a sharp pre-market plunge of 9% on Friday, following the company's fourth-quarter 2024 earnings report and disappointing first-quarter 2025 guidance released after the market close on Thursday.</p>\n\n<p>The medical device maker reported Q4 2024 earnings per share (EPS) of $0.49, in line with analysts' estimates. However, the company's Q4 revenue of $55.7 million missed Wall Street's consensus estimate of $56 million. This revenue miss appears to be the primary driver behind the stock's steep decline in pre-market trading.</p>\n\n<p>Adding to investor concerns, LeMaitre's Q1 2025 revenue guidance of $56.7-$58.7 million also fell short of analysts' expectations, further exacerbating the sell-off. While the company's Q1 EPS guidance range of $0.48-$0.53 was in line with estimates, the weak revenue outlook overshadowed this positive aspect, weighing heavily on the stock's performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LMAT","symbol_name":"勒梅特微管医疗","start_time":0,"source_url":"","article_id":"1180401008","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180401008","pubTimestamp":1740740303,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LeMaitre Vascular  stock is experiencing a sharp pre-market plunge of 9% on Friday, following the company's fourth-quarter 2024 earnings report and disappointing first-quarter 2025 guidance released after the market close on Thursday.The medical device maker reported Q4 2024 earnings per share  of $0.49, in line with analysts' estimates. However, the company's Q4 revenue of $55.7 million missed Wall Street's consensus estimate of $56 million. This revenue miss appears to be the primary driver be","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LMAT":"勒梅特微管医疗"},"translate_title":"由于第四季度营收未达预期和第一季度前景疲软，LeMaitre Vascular盘前暴跌9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LMAT":1},"content_text":"LeMaitre Vascular (LMAT) stock is experiencing a sharp pre-market plunge of 9% on Friday, following the company's fourth-quarter 2024 earnings report and disappointing first-quarter 2025 guidance released after the market close on Thursday.\nThe medical device maker reported Q4 2024 earnings per share (EPS) of $0.49, in line with analysts' estimates. However, the company's Q4 revenue of $55.7 million missed Wall Street's consensus estimate of $56 million. This revenue miss appears to be the primary driver behind the stock's steep decline in pre-market trading.\nAdding to investor concerns, LeMaitre's Q1 2025 revenue guidance of $56.7-$58.7 million also fell short of analysts' expectations, further exacerbating the sell-off. While the company's Q1 EPS guidance range of $0.48-$0.53 was in line with estimates, the weak revenue outlook overshadowed this positive aspect, weighing heavily on the stock's performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}